Member Info for EmeraldCarrots

Gained 15 per cent, or 1.5p, to 11.5p as the developer of a unique liquid biopsy innovation presented new data at the American Association for Cancer Research Special Conference highlighting significant advances in cancer diagnostics.".

https://www.dailymail.co.uk/money/markets/article-14088421/MARKET-REPORT-Nat-Rothschilds-Volex-swoops-TT-Electronics.html

"But on the upside, Angle gained 15 pc, or 1.5p, to 11.5p as the developer of a unique liquid biopsy innovation presented new data at the American Association for Cancer Research Special Conference highlighting significant advances in cancer diagnostics". Market report, page 94.

Should boost the sp back to last Julys placing price of 15p a share I think at least.

All IMHO.

Blood plasma sample all you want, but the proteins are simply not there to find. Not there. Does not matter how good your tech is. You can't test something that simply is not present. The proteins are there in circulating tumour cells though. Angle's Parsortix machine can catch them from a standard blood sample. So what will the CtDNA analysis Companies do????????????? They need to do something soon.

All IMHO.

LOL! I predict that Angle Plc will stop selling the Parsortix machine within the next 6 months. Without live circulating tumour cells to analyse the competition will be snookered as far as offering the dual analysis goes. That is both the already available CtDna analysis of blood plasma (already offered by Illumina etc...) combined with the circulating tumour cell analysis that only Angle offer. The likes of Illumina will fall by the wayside if they are not very careful IMHO.

All IMHO.

If they are not careful. The dual analysys that Angle can do they simply can't offer............ What will they do????

Something has to give..........

All IMHO.

Up 15%.

likely to be taken over @ 50p a share plus IMHO.

All IMHO.

Come on Genedrive. What has been happening? Last update was 15th July! >>

https://www.lse.co.uk/rns/GDR/breakthrough-device-designation-from-the-us-fda-2zclfstav7guqaq.html

Bad for Genedrive, unless you believe some of the posters on here. LOL!

Up 15%.

start (15p a share)! Angle Plc is massively undervalued IMHO.

All IMHO.

Up 15%.

start! Angle Plc is massively undervalues IMHO.

All IMHO.

Https://angleplc.com/wp-content/uploads/2024/11/CBIM-P-B-AACR-Nov2024-PD-L1-status-in-CTC-isolated-from-blood-samples-of-lung-cancer-patients-compressed.pdf

Https://angleplc.com/wp-content/uploads/2024/11/AACR20November20202420HER220B20Version-compressed.pdf

Sometime in the next 6 months. More contracts with major Pharma are IMHO inevitable and then Angle will be being discussed in the board rooms of the most major Pharma Co's in the World.

All IMHO.

PM01.

"Could this be the start of the change in fortunes for AGL?".

=================

Exactly. A few years back Angle raised a load of money to promote the selling of their new Parsortix machine. It can catch live circulating tumour cells (CTC's) which can then be analysed for up to date information about a person’s cancer. Sales of the machine were very disappointing, and a load of money was lost. Reason being developing the assays (tests) to analyse the CTC's is very expensive. Large Pharma Co's for the most part clearly were not willing to spend the money (thus putting cancer research back months if not more than a year IMHO). Shame on them. So, Angle was forced to do the assays themselves, and here we are. Eisai Inc. and Astrazeneca thus far are Angle's main clients. The data from studies over the last few years puts Angle in a fantastic position now. In fact, I suspect as they themselves use the Parsortix machine as a service to the industry there is a chance Angle may stop selling them as other Co's could (if they spent the money!) do their own assays and so compete with Angle............!

All IMHO.

Https://www.proactiveinvestors.com/companies/news/1060259/angle-s-tech-shows-promise-tracking-and-treating-lung-cancer-1060259.html

This is applicable for ANY immunotherapy cancer drug trial anywhere in the wole wide world.........

The sp will simply blast off at some point and 11p to buy will be seen as next to nothing when the sp is 50p plus.

All IMHO.

Parsortix-based pd-l1 assay showcased at international liquid biopsy conference

CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the publication of new data at the American Association for Cancer Research (AACR) Special Conference in Cancer Research, Liquid Biopsy: From Discovery to Clinical Implementation, in San Diego, US from 13 to 16 November 2024.

ANGLE is presenting a poster entitled "Investigating PD-L1 status in circulating tumor cells isolated from the blood samples of lung cancer patients". The poster presentation reports on ANGLE's immunofluorescence assay for the identification of different CTC phenotypes (epithelial, mesenchymal and those transitioning) and the determination of Programmed Death Ligand-1 (PD-L1) status. Analytical verification demonstrated that the assay successfully produced linear data with high analytical sensitivity1 and specificity2 for epithelial, mesenchymal, blood lineage and PD-L1 markers.

PD-L1 allows cancer cells to evade the host immune response when upregulated, and assessment of PD-L1 status in tumour tissue can indicate if immunotherapy has the potential to be an effective treatment. However, lung tissue biopsies can be challenging and expensive and are not always successful, plus PD-L1 status in tumour tissue can become outdated during tumour evolution and may not be representative of metastatic sites. ANGLE has developed a liquid biopsy assay that allows for minimally invasive, longitudinal monitoring of PD-L1 status in CTCs harvested using the Parsortix® system.

The assay identified CTCs in 91% (29/32) of metastatic lung cancer patients assessed as part of an ongoing longitudinal study, presenting with a range of phenotypes. PD-L1 positive CTCs were observed in 72% of patients with a PD-L1 positive tissue biopsy and in 27% of patients with a PD-L1 negative tissue biopsy, demonstrating the potential for improved assessment of tumour heterogeneity through analysis of PD-L1 status in CTCs.

A patient case study revealed that CTC PD-L1 status varied between blood draws, showing discordance with the initial tumour biopsy at multiple time points. The results presented in this study demonstrate the potential for the development of CTC-based dynamic PD-L1 testing to advance personalised treatment for metastatic lung cancer patients.

The poster is available for review at: https://angleplc.com/resources/posters/

RESULTS FROM WORK TO DEVELOP A PARSORTIX-BASED Her2 assay KIT SHOWCASED AT INTERNATIONAL LIQUID BIOPSY CONFERENCE

Parsortix-based HER2 kit being developed to provide an optimised, easily implemented, solution to enable product customers to undertake longitudinal, repeat assessment of HER2 status in breast cancer

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the publication of new data at the American Association for Cancer Research (AACR) Special Conference in Cancer Research in San Diego, US from 13 to 16 November 2024.

ANGLE is presenting a poster entitled the "Development of a scoring system to classify HER2 protein expression in Circulating Tumor Cells through immunofluorescence following isolation using Parsortix® instruments" and reports on progress of the Company's co-development programme with BioView.

Using the high throughput BioView Allegro Plus microscope, ANGLE and BioView are developing an end-to-end assay kit for the evaluation of HER2 gene amplification and protein expression in circulating tumour cells (CTCs) harvested using the Parsortix system from the blood of metastatic breast cancer (MBC) patients.

Results presented showcase the development of a scoring system for HER2 expression, which could be implemented alongside the current standard of care which uses tumour tissue for HER2 assessment. The workflow was assessed in a cohort of 43 MBC patients. The study identified cases where HER2 status had changed over time and patients who were initially HER2 negative had, in the time elapsed since tissue biopsy, become HER2 positive based on their CTC analysis.

Approximately 80% of breast cancer patients are categorised as HER2 negative based on tissue biopsy at diagnosis. However, it is well documented that HER2 status can change over time and a blood-based test could therefore enable the identification of patients who were previously HER2 negative who may now be HER2-low or positive and could therefore benefit from treatment with a HER2-targeted antibody drug conjugate (ADC) or anti-HER2 therapy.

BioView's Chief Scientific Officer, Chassidy Johnson, commented:

"The results ANGLE will present from our co-development work at the AACR Special Conference in Cancer Research are an important milestone in our development programme. The results highlight the ability and robust analytical performance of the developed HER2 CTC assay to detect ranges of HER2 expression therefore potentially identifying patients that could benefit from anti-HER2 therapy as well as newer HER2-targeted ADCs."

To have Angle Plc do the dual analysis just before any trial begins. This way they could identify those volunteers whose cancer's Biomarker has changed to make them no longer suitable for the trial. Then that person would not take part in the trial (as the targeted drug would not work) and they could seek alternative treatment. This would save the Pharma Co. a load of money avoiding treating someone who would not respond to the treatment and possibly save the person’s life. As I said the sp here is just plain stupid low. It is incredible……..

All IMHO.

Genedrive® CYP2C19 ID Kit >>>

https://www.lse.co.uk/rns/GDR/scottish-health-technology-group-publications-uhc1se9rq9j1hy8.html

Seems to make sense now they have recommened it!

All IMHO.

Come on Genedrive. What has been happening? Last update was 15th July! >>

https://www.lse.co.uk/rns/GDR/breakthrough-device-designation-from-the-us-fda-2zclfstav7guqaq.html